<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17081" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Acetylcholinesterase</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Trang</surname>
            <given-names>Amy</given-names>
          </name>
          <aff>Oakland University William Beaumont</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khandhar</surname>
            <given-names>Paras B.</given-names>
          </name>
          <aff>Beaumont Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amy Trang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Paras Khandhar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17081.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acetylcholinesterase (AChE) is a cholinergic enzyme primarily found at postsynaptic neuromuscular junctions, especially in muscles and nerves. It immediately breaks down or hydrolyzes acetylcholine (ACh), a naturally occurring neurotransmitter, into acetic acid and choline.<xref ref-type="bibr" rid="article-17081.r1">[1]</xref>&#x000a0;The primary role of AChE is to terminate neuronal transmission and signaling between synapses to prevent ACh dispersal and activation of nearby receptors. Organophosphates inhibit AChE. They are&#x000a0;an important component of pesticides and nerve agents.</p>
      </sec>
      <sec id="article-17081.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Organophosphates are acetylcholinesterase inhibitors with the potential for exposure and toxicity related to their use as pesticides. Due to widespread use, organophosphates are one of the most common causes of poisoning in the world from agricultural, accidental, or suicidal exposure.<xref ref-type="bibr" rid="article-17081.r2">[2]</xref>&#x000a0;Exposure to organophosphates may cause symptoms such as confusion, headache, and impaired memory and may have neurotoxic effects from repeated exposure. Irreversible acetylcholinesterase inhibitors used as insecticides or nerve agents in warfare pose significant toxicity. These agents induce a cholinergic crisis which includes any combination of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Muscarinic effects, such as miosis, increased secretions (salivation, lacrimation), diarrhea, urination</p>
          </list-item>
          <list-item>
            <p>Nicotinic effects, such as muscle fasciculations and neuromuscular blockade</p>
          </list-item>
          <list-item>
            <p>Central effects: bradycardia</p>
          </list-item>
        </list>
        <p>Organophosphate poisoning is treatable with atropine, an antimuscarinic that reduces the effects of ACh surplus.<xref ref-type="bibr" rid="article-17081.r2">[2]</xref>&#x000a0;Atropine should be given initially at 2 to 5mg intravenous (IV) for adults and 0.05 mg/kg IV for children. Doubling the dose every 3 to 5 minutes until symptoms begin to cease is also appropriate if no relief is noted after the first dose.<xref ref-type="bibr" rid="article-17081.r3">[3]</xref>&#x000a0;Alzheimer dementia (AD) is a prevalent disease that affects memory and cognition. The pathophysiology of cognitive impairment associated with AD has been attributed to a loss of cholinergic neurons.<xref ref-type="bibr" rid="article-17081.r4">[4]</xref> Histologically, B-amyloid plaques and neurofibrillary tangles interrupt synaptic signaling, leading to neuronal cell death.<xref ref-type="bibr" rid="article-17081.r5">[5]</xref>&#x000a0;Since the 1990s, AChE inhibitors have shown some benefits for Alzheimer disease.<xref ref-type="bibr" rid="article-17081.r6">[6]</xref>&#x000a0;Inhibition of AChE results in a decreased breakdown and subsequent accumulation of acetylcholine. This excess acetylcholine leads to increased stimulation of muscarinic and nicotinic receptors, which provides some therapeutic relief for memory deficits in AD.<xref ref-type="bibr" rid="article-17081.r4">[4]</xref>&#x000a0;AChE inhibitors have various levels of penetrance through the blood-brain barrier. Donepezil, rivastigmine, and tacrine are commonly used drugs for Alzheimer disease with good blood-brain barrier penetration. This activity is in contrast to the carbamate AChE inhibitors, neostigmine or pyridostigmine, which are charged quaternary structures at physiologic pH that prevent the crossing of the blood-brain barrier.<xref ref-type="bibr" rid="article-17081.r7">[7]</xref>&#x000a0;While the benefits of acetylcholine modulation therapy are promising, further studies are necessary due to the potential for accumulation of AChE, which may potentially interact with B-amyloid plaques and cause more neurotoxicity than B-amyloid alone.<xref ref-type="bibr" rid="article-17081.r4">[4]</xref><xref ref-type="bibr" rid="article-17081.r8">[8]</xref></p>
      </sec>
      <sec id="article-17081.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>As an enzyme, acetylcholinesterase exists as a monomer that often polymerizes into a dimer with a disulfide bond. Along with Van der Waals forces, 2 dimers may be linked to become tetramers. The tetramers assemble and bind themselves to what is described as &#x0201c;tails&#x0201d; made up of 3 strands. Chemically and immunologically, these tails structurally resemble collagen and may be broken down by collagenases. With an additional disulfide bond, the dimers of the tetramer link to each tail. A study by Brimijoin et al describes the 6 combinations of AChE: 3 forms of the globular structure (monomers, dimers, tetramers) and 3 forms of tetramers (tailed, double, triple).<xref ref-type="bibr" rid="article-17081.r9">[9]</xref>&#x000a0;Globular AChE is labeled with a &#x0201c;G,&#x0201d; and tailed AChE is labeled with an &#x0201c;A.&#x0201d; Different forms have numerical subscripts associated with each letter to denote the number of their catalytic subunits. For example, a globular monomer is &#x0201c;G1,&#x0201d; and a globular tetramer is &#x0201c;G4&#x0201d;; meanwhile, a triple tetramer with a tail is &#x0201c;A12.&#x0201d;<xref ref-type="bibr" rid="article-17081.r9">[9]</xref></p>
      </sec>
      <sec id="article-17081.s4" sec-type="Development">
        <title>Development</title>
        <p>Although the primary function of AChE is to terminate neural transmission, investigators have found that AChE also plays a role in neural development. Embryologically, AChE is intricately involved in the development of the nervous system and is expressed by developing neurons and during periods of axonal growth (a time in which enzymatic activity does not seem to be most important). In the peripheral nervous system of chicks, transient AChE activity was found to be locally present in the dorsal root ganglions. These findings suggest that during fetal development, AChE contributes to morphogenesis in addition to its main enzymatic function.<xref ref-type="bibr" rid="article-17081.r10">[10]</xref></p>
      </sec>
      <sec id="article-17081.s5" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>Acetylcholinesterase is known to be distributed in nervous tissue such as the brainstem, cerebellum, and peripheral and autonomic nervous systems. Skeletal muscle also contains AChE with distribution patterns seemingly related to the type of muscle (fast versus slow twitch) and their specific function.<xref ref-type="bibr" rid="article-17081.r9">[9]</xref>&#x000a0;The presence and function of AChE on red blood cells are less commonly known. Blood group antigens reside on the outer lipid bilayer of red blood cells for convenient antibody recognition. In the same regard, AChE is also present in red blood cell membranes.<xref ref-type="bibr" rid="article-17081.r11">[11]</xref></p>
      </sec>
      <sec id="article-17081.s6" sec-type="Function">
        <title>Function</title>
        <p>The neurotransmitter acetylcholine is released when a neural signal propagates and excites or activates a cellular membrane. Consequently, the ACh receptor undergoes a conformational change, and the membrane releases calcium ions. These calcium ions play a role in exciting the fibers of nerves and muscles by triggering an additional change in phospholipids. Essentially, the downstream effect of a signal initiated with ACh results in the amplification and propagation of cellular signaling.<xref ref-type="bibr" rid="article-17081.r12">[12]</xref></p>
      </sec>
      <sec id="article-17081.s7" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>The interaction of acetylcholinesterase with the substrate acetylcholine results in the breakdown, hydrolysis, and inactivation of acetylcholine and subsequent control of the amount of ACh at the synapse. AChE is a serine hydrolase that creates a tetrahedral intermediate through acid-base reactions with a catalytic triad (serine, histidine, acid residue).<xref ref-type="bibr" rid="article-17081.r8">[8]</xref>&#x000a0;Histidine allows for the transference of a proton between the oxygen molecules in serine and ACh, thereby removing choline to form a new acylated serine. When the acylated serine is deacylated, the regeneration of free AChE begins. In this reaction, aspartate stabilizes the protonated histidine, which releases acetic acid and a new, free enzyme. The interaction between amino acid residues (tyrosine, phenylalanine, tryptophan) that make up a peripheral anionic site influences the conformational binding of ACh to that site.<xref ref-type="bibr" rid="article-17081.r1">[1]</xref></p>
      </sec>
      <sec id="article-17081.s8" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>Positron emission tomography imaging of cortical AChE activity in vivo has been used to measure the efficacy of dementia therapy. There are reports of decreased activity of acetylcholinesterase in patients with Alzheimer disease. By measuring AChE activity and using it to gauge cholinergic innervation expressed by axons and nerves, investigators may configure and assess the efficacy of cholinesterase inhibitors as it contributes to the management of Alzheimer disease.<xref ref-type="bibr" rid="article-17081.r13">[13]</xref></p>
      </sec>
      <sec id="article-17081.s9" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The human brain has a confluence of cholinergic neurons that project to various cortical areas. These neurons control attention, thinking, and processing of stimuli. Not only do cholinergic neurons span the forebrain, but they also encompass the brainstem and thalamus (such as the reticular nucleus), which are responsible for consciousness and attention. In the context of Alzheimer dementia as a neurodegenerative disease, these cholinergic neurons have defective projections that correlate with the classic symptoms of cognitive slowing and decline.<xref ref-type="bibr" rid="article-17081.r13">[13]</xref>&#x000a0;The disease is well known for declining short-term memory, atrophy of the cerebrum, B-amyloid plaques, tangles, and tau protein deposits.<xref ref-type="bibr" rid="article-17081.r1">[1]</xref></p>
      </sec>
      <sec id="article-17081.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Patients with Alzheimer disease often receive treatment with acetylcholinesterase inhibitors that mitigate symptoms by hindering ACh turnover. In effect, lingering levels of ACh help recalibrate the neurotransmitter to appropriate and adequate levels.<xref ref-type="bibr" rid="article-17081.r5">[5]</xref>&#x000a0;Inhibition of AChE raises the concentration of ACh at the synaptic junction and allows for the potentiation of the signal. This action ultimately reduces the amount of choline uptake and increases the number of muscarinic M2 receptors. In those treated with AChE inhibitors, a deceleration of the progression of the disease, as well as an increased attention span, has been reported. However, no significant signs of increased short-term memory have been noted in the current literature.<xref ref-type="bibr" rid="article-17081.r1">[1]</xref></p>
        <p>Despite the apparent benefit of AChE inhibitors for the management of Alzheimer disease, recent studies have stated that the application of such inhibitors fails to address the pathology in its entirety. Nordberg et al. have found that some AChE inhibitors, such as donepezil or galantamine, show increased levels of AChE in CSF.<xref ref-type="bibr" rid="article-17081.r14">[14]</xref>&#x000a0;An imbalance of AChE can worsen Alzheimer dementia, as complexes of AChE-amyloid-B show higher levels of toxicity than amyloid-B plaques alone.<xref ref-type="bibr" rid="article-17081.r4">[4]</xref>&#x000a0;Such findings warrant a reassessment of current treatment options for the disease, as these drugs may have an underlying potential to worsen the pathologic state of Alzheimer disease.<xref ref-type="bibr" rid="article-17081.r8">[8]</xref>&#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-17081.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17081&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17081">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17081/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17081">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17081.s12">
        <title>References</title>
        <ref id="article-17081.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McHardy</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>McCowen</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Valdez</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).</article-title>
            <source>Expert Opin Ther Pat</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>455</fpage>
            <page-range>455-476</page-range>
            <pub-id pub-id-type="pmid">27967267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colovi&#x00107;</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Krsti&#x00107;</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Lazarevi&#x00107;-Pa&#x00161;ti</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Bond&#x0017e;i&#x00107;</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vasi&#x00107;</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase inhibitors: pharmacology and toxicology.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2013</year>
            <month>May</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-35</page-range>
            <pub-id pub-id-type="pmid">24179466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konickx</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bingham</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eddleston</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Is oxygen required before atropine administration in organophosphorus or carbamate pesticide poisoning? - A cohort study.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>531</fpage>
            <page-range>531-7</page-range>
            <pub-id pub-id-type="pmid">24810796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazarevic-Pasti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leskovac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Momic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petrovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vasic</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.</article-title>
            <source>Curr Med Chem</source>
            <year>2017</year>
            <volume>24</volume>
            <issue>30</issue>
            <fpage>3283</fpage>
            <page-range>3283-3309</page-range>
            <pub-id pub-id-type="pmid">28685687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rees</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Brimijoin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-83</page-range>
            <pub-id pub-id-type="pmid">12669110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGleenon</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Dynan</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Passmore</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase inhibitors in Alzheimer's disease.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>471</fpage>
            <page-range>471-80</page-range>
            <pub-id pub-id-type="pmid">10583015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pohanka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.</article-title>
            <source>Int J Mol Sci</source>
            <year>2014</year>
            <month>Jun</month>
            <day>02</day>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>9809</fpage>
            <page-range>9809-25</page-range>
            <pub-id pub-id-type="pmid">24893223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soreq</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholinesterase--new roles for an old actor.</article-title>
            <source>Nat Rev Neurosci</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>294</fpage>
            <page-range>294-302</page-range>
            <pub-id pub-id-type="pmid">11283752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brimijoin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics.</article-title>
            <source>Prog Neurobiol</source>
            <year>1983</year>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-322</page-range>
            <pub-id pub-id-type="pmid">6198691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bigbee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Dupree</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Morphogenic role for acetylcholinesterase in axonal outgrowth during neural development.</article-title>
            <source>Environ Health Perspect</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>107 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>81</fpage>
            <page-range>81-7</page-range>
            <pub-id pub-id-type="pmid">10229710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartels</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Zelinski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lockridge</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism.</article-title>
            <source>Am J Hum Genet</source>
            <year>1993</year>
            <month>May</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>928</fpage>
            <page-range>928-36</page-range>
            <pub-id pub-id-type="pmid">8488842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leuzinger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of acetylcholinesterase.</article-title>
            <source>Prog Brain Res</source>
            <year>1969</year>
            <volume>31</volume>
            <fpage>241</fpage>
            <page-range>241-5</page-range>
            <pub-id pub-id-type="pmid">4899409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herholz</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>35 Suppl 1</volume>
            <fpage>S25</fpage>
            <page-range>S25-9</page-range>
            <pub-id pub-id-type="pmid">18196237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17081.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Darreh-Shori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peskind</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soininen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mousavi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.</article-title>
            <source>Curr Alzheimer Res</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-14</page-range>
            <pub-id pub-id-type="pmid">19199870</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
